26 Jul Quell Therapeutics
Luke Henry, Ph.D., Chief Business Officer
Oct. 7 | 9:00am | FLW Ballroom F
London, UK
(Private)
Quell Therapeutics is developing engineered T-regulatory (Treg) cell therapies that aim to harness, direct and optimize their immune suppressive properties to address serious medical conditions driven by the immune system. Quell is leveraging its pioneering Foxp3 Phenotype Lock™ technology, unique multi-modular platform and integrated manufacturing capabilities to design and develop a pipeline of highly engineered Treg cell therapies with greater potential for stability, potency and persistence. Quell’s lead CAR-Treg candidate QEL-001 is being developed to induce operational tolerance following Liver Transplantation, with the potential to protect the liver grat without the need for chronic immunosuppressive medications. Quell has multiple preclinical CAR-Treg programs in autoimmune and inflammatory diseases, both internally and within a strategic partnership with AstraZeneca
